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Abstract 
 
Gram-negative bacteria make up the majority of dangerous health-care associated 
infections (HAIs), and are becoming increasingly resistant to standard antibiotics. The 
Beta Barrel Assembly Machine (BAM) is a protein complex in Gram-negative bacteria 
composed of BamA, an essential member of the Omp85 family, and four associated 
lipoproteins B-E. The BAM is present in all Gram-negative bacteria and has a pivotal 
role in outer membrane protein (OMP) insertion, making it an attractive target for study 
and the development of new antibiotic agents. This investigation probes the importance 
of conserved residues in BamA, the central component of the BAM complex, and 
suggests the hypothesis that it may form higher order assemblies important for outer 
membrane biogenesis. The ConSurf bioinformatics server was used to identify highly 
evolutionarily conserved surface amino acids that could have putative functional 
importance. Tryptophan scanning and complementation assays were carried out to 
characterize potentially functionally important residues directed by this bioinformatics 
analysis. In addition, single cysteine residues were introduced in the periplasmic domain 
of BamA and used in crosslinking experiments in an attempt to trap and identify 
interacting partners. One tryptophan mutant, R36W, failed to complement, suggesting 
mechanistic importance. Strong crosslinking was observed in cysteine mutants T53C and 
R160C, supporting a model where BAM organizes into higher order assemblies to 
mediate folding and insertion of beta-barrel outer membrane proteins. 
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Introduction 
 
The Dangers of Antibiotic Resistance  
Antibiotic resistance is a reality of modern medicine, and as such it constitutes a 
significant public health risk. Bacteria, mycobacteria, viruses, parasites, and fungi are 
treated with antimicrobials, but microbes themselves continually evolve new resistance 
mechanisms-- in many ways evolutionarily pressured by the very treatments that are 
designed to eradicate them 
[1]. This is a grave and 
cascading problem in today’s 
healthcare system, in which a 
patient admitted to the 
hospital for one illness may 
die of secondary 
complications arising from the 
drug-resistant, pathogenic 
microorganisms that often 
inhabit health care settings. 
Nosocomial infections are 
consistently in the top ten 
leading causes of death in the United States; yearly, nearly 100,000 deaths are attributed 
to healthcare associated infections (HAIs): this is comparable with the number of 
accidental traumatic deaths, which includes automobile accident mortalities [3, 4]. Not 
only do HAIs cause many deaths, but these are deaths that may once have been 
preventable. With increasing antibiotic resistance, health care professionals may be 
forced to provide supportive care for a drug-resistant infection rather than treating the 
infection itself, and they must also be wary of spreading a particular strain of resistant 
infection to other vulnerable patients. 
 
“Antimicrobial” is a general term that encompasses the drug field of antibiotics, agents 
that kill or inhibit the replication of bacteria. The focus of this research is to study an 
Figure 1: Number of antibacterial New Drug Application 
approvals per year interval. Despite the increasing demand for 
new antibiotics, NDAs for new antimicrobial agents have declined 
greatly since the early 1900’s. Figure from [2]. 
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essential protein complex in Gram-negative bacteria, the Beta Barrel Assembly Machine 
(BAM), with the ultimate hope of informing the design of a novel class of antibiotic. 
Antibacterial resistance is a non-trivial problem, particularly in hospitals and retirement 
homes, and particularly because the discovery of novel classes of antibiotics has slowed 
dramatically [2]. Gram-negative bacteria, so named because the cells fail to take up the 
eponymous Gram dye, distinguish themselves from Gram-positive bacteria by being 
more typically (and intrinsically) prone to antibiotic resistance [5]. Gram-negative 
bacteria make up an estimated 70% of all ICU infections, making Gram-negative species 
a significant concern in health care settings [6]. In a Canadian survey, E. coli and P. 
aeruginosa (two of the most common Gram-negative HAIs) were responsible for more 
than 12% of all multidrug-resistant isolates, which require aggressive treatment with so-
called “last-chance” antibiotics, an action that is not always successful [7]. In hospital 
settings, Gram-negative bacteria are one of the most dangerous elements of patient care: 
Gram-negative bacteria predominate in cases of ventilator-associated pneumonia 
and hospital-acquired urinary tract infections, and make up 30% of bloodstream 
infections acquired in health care settings [6, 8]. The scale of the problem of drug-
resistant Gram-negative enterobacteria like E. coli is such that, for instance, the United 
States Center for Disease Control lists carbapenem-resistant E. coli as a threat to public 
health requiring “urgent and aggressive action” due to their resistance to nearly all 
antibiotics [2].  
 
Currently, more than one hundred different resistance genes in bacterial plasmid DNA 
have been described. Due to selection pressure caused by the advent and 
institutionalization of antibiotics in the 1940s, there has been a significant present-day 
increase in the number of bacterial plasmids containing resistance genes versus the pre-
antibiotics era [9, 10]. This has very real repercussions.  Admittance for an inpatient 
hospital procedure for a range of diverse procedures has a typical length of stay of two to 
four days; ten years ago, the average hospital stay time was twice that [11]. Today, a long 
hospital stay presents increased opportunities for infection with drug-resistant 
microorganisms-- making it safer to send patients home sooner, where the likelihood of 
encountering drug-resistant bacteria is less probable. Any interaction with health-care 
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settings now brings a secondary threat of possibly antibiotic-resistant nosocomial 
infection. 
 
Hospitals and healthcare establishments clearly perpetuate the problem of antibiotic 
resistance; previous and current medical practice espouses the over-prescription of 
antibiotics, thus providing evolutionary selection criteria for bacteria. A sobering 
example concerns the often unnecessary prescription of antibiotics for upper-respiratory 
infections, which are nearly always viral, and for which nearly half of patients in the 
United States are issued an antibiotic prescription [11]. Antibiotics are also used in 
animal husbandry, resulting in low antibiotic levels in food supplies, soil, and water 
runoff from feedlots and slaughterhouses. Tap water servicing residential areas 
downstream of pharmaceutical production has even demonstrated appreciable levels of 
antibiotics and other pharmaceutical agents [12].  
 
The low levels of antibiotic drugs chronically present in a developed environment put 
forth an additional worry regarding antibiotic resistance; the trace amounts of antibiotics 
in drinking water and soil and the use of household antibiotics in the home, in daycares, 
and elsewhere exert a “non-lethal” pressure on bacteria, resulting in a potentially larger 
selection window for resistance than when lethal concentrations of antibiotic agent are 
used [13]. The implications if this finding are large: not only must the spurious use of 
antibiotics be curtailed (and protocols have been initiated to do so), but new antibiotics 
must be discovered in order to stay ahead of cascading resistance [14].  
 
In light of the significant public health problem presented by Gram-negative 
infections, efforts are needed in the development of drugs that may inhibit 
resistance, as well as identification of targets for novel classes of antibiotics to treat 
resistant infections. This research aims to understand the protein BamA, a 
component of the Beta-Barrel Assembly Machine (BAM) complex, a protein 
complex that is integral in outer membrane protein biogenesis. Outer membrane 
protein biogenesis is an essential process in Gram-negative bacteria, and 
understanding this process may provide a new antibiotic drug target.  
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Gram-negative Bacteria Overview 
 
Gram-negative bacteria include Escherichia coli, Salmonella typhimurium,, and other 
bacteria responsible for a variety of illnesses as diverse as pneumonia and hemorrhagic 
colitis.  Gram-negative bacteria are unique due to their asymmetrical outer membranes. 
The inner membrane, composed of a typical phospholipid bilayer, is fluid and relatively 
permeable. The outer membrane, by contrast, is composed of lipopolysaccharides (LPS) 
in the outer leaflet, with the most common lipid attachment being Lipid A. The role of 
LPS in the outer membrane is to decrease fluidity in the outer membrane. Lipid A 
attachments can further form self-associations through electrostatic interactions of 
divalent cations, forming a charged permeability barrier against possibly hostile 
molecules [15]. Alterations to the polysaccharide attachment of the O antigen as well as 
Lipid A help some bacteria evade immune cells [15, 16].  The increase in the 
permeability threshold due to LPS in the outer membrane gives Gram-negative bacteria a 
degree of intrinsic antibiotic resistance. Between the two membranes is a peptidoglycan 
wall which, though it does present a target for the beta-lactam class of antibiotics, is 
extremely permeable to most molecules, allowing the passage of compounds as large as 
30-57 kDa [17, 18]. 
  
  
Figure 2: Gram-negative bacterial overview. The asymmetric outer membrane of gram negative bacteria 
decreases the organism’s permeability to antibiotic agents. Figure adapted from [19]. 
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The Beta-Barrel Assembly Machine (BAM)  
 
Outer Membrane Proteins (OMPs) 
in gram negative bacteria are 
synthesized in the cytoplasm and 
cross the inner membrane via 
machinery like the SecYEG 
translocon [20, 21]. Nascent 
proteins move through the 
periplasmic space to be inserted 
into the outer membrane by a 
mechanism that is only beginning 
to emerge. This insertion process is 
essential to import of nutrients for 
the survival of Gram-negative 
bacteria, including the human pathogens Escherichia and Neisseria [22]. In addition, 
bacteria unable to carry out this mechanism efficiently have been shown to be more 
susceptible to antibiotics, a change in membrane permeability related to secondary effects 
on the machinery that introduces LPS to the outer leaflet of the outer membrane [23]. The 
multi-protein complex called the beta-barrel assembly machine (BAM) has been 
described as a crucial element of OMP insertion [24]. As shown schematically in Figure 
3, the BAM is composed of one essential protein in the Omp85 family, BamA, as well as 
four lipoproteins, BamB, C, D, and E, of which only BamD is essential in E. coli [23]. 
Structures have been solved for BamA, B, C, D, and E [25-35]. BamA is composed of a 
beta barrel that traverses the outer membrane, as well as a periplasmic domain that likely 
behaves as an anchor for the associated lipoproteins [15, 30, 31]. Notably, BamA is found 
in all Gram-negative bacteria and is therefore an interesting target for study [34]. The 
periplasmic domain of BamA contains five polypeptide transport-associated (POTRA) 
domains. These water-soluble domains are thought be involved in protein-protein 
interactions, to initiate beta-strand formation in unfolded OMPs, and to have chaperone-
like activity in OMP folding and insertion [32, 34, 35].  
 
Figure 3: The Beta Barrel Assembly Machine. The BAM is 
composed of BamA and four associated lipoproteins, BamB, 
C, D, and E. Figure from [26]. 
 
   
9 
 
Studies of the POTRA domains have indicated that the POTRA “arm” has a crucial role 
in OMP insertion; deletions of POTRA subunits result in varied phenotypes depending on 
the specific POTRA domain being deleted. Only POTRAs 3-5 appear to be essential in E. 
coli. However, when only POTRAs 1 or 2 are eliminated there are significant decreases 
in the correct insertion of OmpA, a predominant outer membrane protein, reflecting 
decreased efficiency in OMP biogenesis. DegP, a protease for misfolded proteins in the 
periplasm, is upregulated, presumably to process the increase in poorly folded OMPs 
[34]. 
 
Hypothesis and Rationale: A Model for OMP Insertion 
 
The current proposed mechanism for 
OMP insertion relies on the behavior 
of BamA and the POTRA domains as a 
scaffold. In this model, the actual 
transfer of nascent proteins from the 
cytoplasm occurs via protein 
chaperones Skp, DegP, and SurA as 
the protein emerges from the SecYEG 
translocon and other transporters in the 
inner membrane [36]. The SecYEG 
translocon is an ATP-dependent Type 
II secretion system transporter that 
brings unfolded OMPs via signal 
peptide recognition from the cytoplasm 
[37].  
 
Figure 4 shows an unfolded protein as 
it is translocated through SecYEG, after which chaperones Skp and SurA bring the 
protein to the BAM complex, which folds and releases the protein into the outer 
membrane by an unknown mechanism. In this model, DegP degrades incorrectly-folded 
proteins that fail to be properly inserted. The POTRA domains (labeled P1-P5) do not 
Figure 4: OMP Biogenesis. SecYEG translocates nascent 
OMPs from the cytoplasm to the periplasm. Chaperones 
SurA, Skp and DegP together with BamABCDE transport, 
fold and insert OMPs into the outer membrane. The 
mechanism of insertion is unknown. Figure from [38]. 
. 
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have a well-defined role within the current model for OMP insertion, although it has been 
shown that they can bind peptides and lipoproteins [35, 39].  POTRA deletion studies 
suggest that POTRAs 3-5 bind BamB and the BamCDE complex [34]. It has also been 
suggested that the POTRA domains, which have been shown to bind short peptides 
originating from OMPs, can initiate beta strand formation through beta-augmentation, 
thus aiding nascent OMP folding before insertion [35, 39- 41]. 
 
It has been suggested that SurA is the primary chaperone aiding BamA in the folding and 
transport of OMPs [42, 43]. It has been shown that SurA interacts with BamA in vivo 
[44].  This leaves DegP and Skp with a redundant role degrading misfolded proteins and 
possibly rescuing proteins lost by SurA. In SurA deletion mutants, DegP and Skp are 
both upregulated, presumably to compensate for the SurA deficiency [42]. However, 
double mutants depleting both Skp and SurA are not always lethal, notably in Neisseria 
meningitidis, implying the existence of 
a third redundant mechanism beyond 
the action of the Skp and SurA 
pathways [43].   
 
The Sousa lab has determined the 
structure of BamA’s periplasmic 
POTRA arm, albeit in a truncated form 
lacking POTRA 5 due to difficulty 
purifying the full periplasmic domain 
[32, 35]. Later work defined the 
structure of the complete periplasmic 
domain containing all five POTRA 
domains through a combination of X-ray crystallography, Nuclear Magnetic Resonance 
(NMR) and Small Angle X-ray Scattering (SAXS) [25]. Previous work uncovered the 
finding that the POTRA arm of BamA adopts at least two conformations via a hinged 
region between POTRA 1 and POTRA 2; SAXS data has confirmed that the POTRA arm 
exists preferentially in both bent and extended conformations (see Figure 4) [35]. The 
Figure 5: Bent and extended conformations of 
periplasmic POTRA domains of BamA. A “hinge” 
between P2 and P3 allows for a dynamic conformational 
change of the periplasmic domain of BamA. Figure from 
[34]. 
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POTRA arm in its extended conformation is about 140 angstroms, a length that is 
consistent with the distance between the two membranes in the periplasmic space [35]. 
Thus, it is physically possible for the POTRA arm to reach and interact with inner 
membrane components. This informs my hypothesis, that in addition to the model 
for OMP folding and insertion proposed previously, the POTRA domains of BamA 
interact physically with inner membrane components, allowing for the direct 
transfer of OMPs from the inner to the outer membrane.  The periplasmic arm has a 
number of peptide binding motifs, suggesting that the arm could function as a 
transperiplasmic folding envelope for nascent OMPs [35]. As mentioned, deficiencies of 
the chaperones Skp and SurA do not always result in a lethal phenotype, suggesting that a 
third compensating mechanism of OMP biogenesis exists [43]. A higher-order folding 
envelope formed between the two membranes by the periplasmic domain of BamA would 
be an elegant solution to a currently incomplete model for OMP biogenesis.   
 
Specific Goal 
 
To test my hypothesis, namely that BamA’s POTRA domains interact with the inner 
membrane to form a trans-periplasmic protein folding envelope, I will mutate several 
surface amino acids via site-directed mutagenesis to search for residues involved in 
possible protein-protein interactions with inner membrane components. This will be 
achieved by  
1) identifying residues of functional interest based upon their degrees of phylogenetic 
conservation; 
2) attempting to disrupt protein-protein interactions through mutations to tryptophan, a 
large, sterically hindering amino acid, and observing the effects via complementation 
assay; also  
3) through the use of chemical crosslinkers, attempting to “trap” interactions between 
mutant versions of BamA containing the amino acid cysteine and inner membrane 
proteins. 
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Results 
Bioinformatics Analysis of BamA POTRA Domains 
The ConSurf server uses phylogenetic relationships between homologs to estimate the 
rate of evolutionary change of amino acid residues and positions. The benefits of ConSurf 
over other algorithms are that ConSurf’s calculations take into account amino acid 
chemical similarity as well as relationships between homologous proteins in different 
phylogenetic branches [45]. The server provides a variety of user-mandated options. In 
this case, the Sousa Lab crystal structure for BamA POTRAs 1-4 was uploaded to the 
ConSurf server via its Protein Database identification name 3EFC. ConSurf then 
extracted the amino acid sequence from this structure and searched for homologous 
sequences via CS-BLAST (Context-Specific Basic Alignment Search Tool).  
 
CS-BLAST is differentiated from BLAST on the basis that its calculations take into 
account the environment of specific residues; for instance, a lysine exposed on the 
surface will be less likely to mutate than a lysine buried inside a protein, increasing 
entropic disorder. This difference enables CS-BLAST to find more homologs with fewer 
iterations and comparable error to its BLAST precursor [46]. ConSurf also utilizes Li and 
Godzik’s CD-HIT program to cluster similar sequences, providing a threshold to discard 
highly similar homologs [47]. This increases accuracy of the entire estimate, as sequences 
that come from different organisms and phylogenetic branches offer more compelling 
data if residues are functionally conserved. CD-HIT constructs the Non-Redundant (NR) 
database, discarding duplicates of the seed sequence of the cluster, thus minimizing the 
possibility of false positives due to a particular sequence’s overrepresentation in any pool 
of homologs. This is particularly important for an organism like E. coli, for which there 
are many genomic sequences available. The maximum number of homologs was set to 
300, with identity of 95% (see Methods section). 
 
Homologs were then organized into a Multiple Sequence Alignment (MSA) using default 
program MAFFT (Multiple Alignment Using Fast Fourier Transform) [48]. A 
phylogenetic tree was then built from this alignment using Rate4Site [49]. However, 
ConSurf improves this algorithm by computing conservation scores with regard to 
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position using Bayesian algorithms rather than Rate4Site’s original Maximum Likelihood 
principle. It has been shown that using the Bayesian method reflects more accurate 
phylogenetic branch lengths and site-specific evolutionary rates in a wider range of 
conditions, making it an attractive method for this project, in which the phylogenetic 
branch lengths were unknown [50]. These calculations also generate confidence scores, 
which necessarily become smaller (implying more accuracy) when more varying 
homologous sequences are input. The JTT evolutionary model is used as a default by the 
ConSurf server [51]. 
 
Preliminary analysis of the POTRA domains of BamA suggests that portions of POTRAs 
1 and 2 (those which hypothetically could interact with the inner membrane) offer fruitful 
residues to investigate.  Figure 6 shows graded conservation scores of surface amino 
acids in the periplasmic 
portion of BamA; there 
is a high degree of 
conservation between 
POTRAs 1 and 2, 
suggesting some 
evolutionarily 
conserved function.  
 
Residues to be modified 
by point mutation to 
tryptophan or cysteine 
were chosen primarily 
according to their 
conservation score 
given by the ConSurf 
bioinformatics tool. 
This was to direct experiments to optimize chances of success. Ideally, these single 
amino acid mutations would affect protein-protein or protein-phospholipid interactions 
Figure 6: ConSurf analysis of POTRA domains 1-4 of BamA. ConSurf 
bioinformatics analysis shows a number of highly conserved amino acid 
residues between POTRAs 1 and 2, shown in dark magenta. Residues 
chosen to mutate are mapped as shown. Residues of interest are R36, R160, 
and R162 in the loop linking P1 and P2, as well as T53 at the C-terminal 
end of P1. 
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between the inner membrane and the POTRA domains, but would not affect the 
solubility, expression, or net folding of BamA.  
 
An interesting outcome of 
the ConSurf analysis is 
that the conserved patch 
between POTRAs 1 and 2 
is largely composed of 
arginines, asparagines, 
and glutamines. This 
gives a positively charged 
cluster linking POTRAs 1 
and 2, a pattern of similar 
adjacent residues that 
appears to be exaggerated 
only in this region (Figure 
7).  
 
The conserved residues 
observed in this region are 
capable of forming electrostatic interactions and hydrogen bonds, potentially aiding in 
protein-protein interactions or interactions with the phospholipid heads of the inner 
membrane. The ConSurf bioinformatics results therefore offered several targeted amino 
acid residues for study to attempt to discover functional importance. 
 
As shown in Figures 6 and 7, three residues were chosen to mutate in the conserved area 
between POTRAs 1 and 2. Additionally, a residue was chosen at the end of POTRA1 
based upon its intermediate conservation score (4) as well as its presumed proximity to 
elements of the inner membrane when the periplasmic domain of BamA is in its extended 
conformation. This identified, in total, four residues of interest: R36, R160, R162, and 
T53. 
Figure 7: Illustration of positively charged area of POTRA1-2 link. 
Positive charges are shown in blue, with negative charges in red. The 
conserved area between POTRAs 1 and 2 corresponds with a unique area 
of positive charge that may mediate protein-protein interactions. 
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Cloning of BamA Mutants 
 
Site-Directed Mutagenesis: The desired mutations chosen via conservation score or 
supposed proximity to the Sec machinery were 
introduced to an available pET41a(+) variant 
encoding  full-length, hexahistidine-tagged BamA 
including an N-terminal signal sequence targeting 
the protein to the outer membrane. This plasmid 
was chosen due to its suitability for cloning and 
ease of purification, but it was not intended for 
protein expression owing to the insertion of the 
BamA gene backwards with respect to the T7 
promoter.  
 
Tryptophan scanning complementation 
experiments required single mutations to 
tryptophan in the periplasmic domains of BamA. 
Three residues were chosen for mutation based upon their conservation score obtained 
from ConSurf: R160, R162, and R36, all of which are situated in the bridge between 
POTRAs 1 and 2. These residues were mutated to tryptophan via site-directed 
mutagenesis using the Stratagene Quickchange protocol (see Methods).  
 
Tryptophan scanning was choses versus mutations to other amino acids (i.e. alanine or 
leucine) due to the residue’s large size and intermediate hydrophobicity. The size of 
tryptophan may sterically hinder interactions between POTRAs 1 or 2 and other proteins. 
Its mildly hydrophobic character may also prevent interactions between the soluble 
POTRA domains and the soluble, periplasm-facing portions of the inner membrane 
proteins or phospholipids with which BamA is most likely able to interact. Alternatively, 
although tryptophan is more favorably buried in protein interiors, one tryptophan residue 
exposed to solvent is unlikely to have an aggregating destabilizing entropic effect. 
Figure 8: pET-41a(+) vector map. A 
parent vector consisting of the above pET-
41a(+) expression system including the 
gene for BamA cloned into the multiple 
cloning site was used to create tryptophan 
and cysteine mutants for complementation 
and crosslinking assays. Figure from [53].  
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Typtophan scanning has been used effectively to demonstrate structure and mechanism of 
various proteins [52]. 
To create the mutations necessary 
for complementation and 
crosslinking experiments, primers 
were designed to be ~30 
nucleotides long with at least 15 
nucleotides flanking the desired 
mutation, complementary to the 
coding and noncoding strands of 
the gene for BamA. Primers 
additionally had Guanine/ 
Cytosine content greater than 
40%, ensuring melting 
temperatures within range for 
efficient annealing. Similar 
primers were designed to create cysteine mutants of conserved residues close to the 
terminal end of POTRA1, intended for cross-linking experiments with amine-to-
sulfhydryl specific crosslinkers.  
 
These plasmids were amplified via Polymerase Chain Reaction (PCR), digested with 
DpnI to eliminate the parent vector, and transformed into XL-10 gold E. coli cells, which 
were miniprepped to provide DNA for downstream applications. This resulted in the 
three tryptophan mutants, R36W, R160 W, and R162W, and two cysteine mutants, T53C 
and R160C. A fourth tryptophan mutant, T53W, was unable to be transformed 
successfully. Plasmids were sequenced to confirm mutation of interest as well as to 
screen for additional unintentional mutations arising from polymerase proofreading 
errors. 
 
 
 
Figure 9: PCR amplification of pET plasmids encoding 
BamA mutants. 0 .8% agarose gel in 0.5% TAE containing 
EtBr loaded with 10 μL PCR reaction and run at 130V for 30 
minutes. Plasmid amplification can be seen at ~9 Kb. The 
Stratagene protocol for site-directed mutagenesis was used to 
amplify DNA (see Methods), after which methylated parent 
DNA was digested 16 hours at 37 °C with DpnI. 
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Figure 10: pZS21 plasmid vector map. The pZS21 
vector encodes a kanamycin resistance cassette and is 
low-copy. Genes cloned into the multiple cloning site are 
transcribed under a tetracycline-inducible promoter. 
Figure from [54]. 
Transfer of BamA Tryptophan Mutants to a low-copy number plasmid:  
 
A complementation assay was used to 
test functionality of the tryptophan 
mutants described. A mutant strain of 
E. coli cells encoding the wild-type 
BamA gene under an arabinose-
inducible promoter was used to this 
end. To complete this assay, it was 
necessary to move mutant genes to a 
low copy number plasmid encoding 
BamA mutants under a constitutive E. 
coli promoter, such that functional 
BamA expressed from the plasmid 
gene could “rescue” JCM166 cells 
grown in the absence of arabinose. The 
vector chosen for this purpose was a 
pZS21 plasmid (Figure 10).  
 
Gene transfer was achieved through enzyme digest and ligation of BamA inserts into a 
pZS21 backbone. A pZS21 variant encoding GFP was used as the parent vector. This 
parent was digested with the enzymes EcoRI and XbaI (as were BamA inserts from site-
directed mutagenesis), excised, purified, and ligated with BamA inserts with 
complementary sticky ends (Figure 11). Resulting ligations were verified by sequencing. 
   
18 
 
 
Cysteine Mutants of BamA Intended for Crosslinking Experiments: Though the original 
mutations made in a pET41a cloning vector were optimal for cloning and sequencing 
purposes, they were unsuitable for crosslinking experiments, which necessarily require 
protein expression. Thus, it was necessary to design primers to amplify the BamA mutant 
gene while adding restriction digest sites to ligate the gene of interest into a different 
existing pET vector suitable for expression. Primers were designed to be complementary 
to the leading and lagging strands of the BamA gene until 5’ and 3’ restriction sites were 
added. In this case, primers included sites for NdeI (5’ end of coding strand of BamA) 
and EcoRI (3’), plus an additional 6-nucleotide “tail” to facilitate enzyme recognition and 
digestion. Using these primers, the gene encoding BamA was amplified with the added 
restriction sites. This insert was digested, purified, and ligated into similarly doubly-
digested pMS282, an available pET41a(+) variant encoding a kanamycin resistance 
cassette (see Figure 8) and BamC.  
 
Figure 11: Enzyme digestion of pET mutants and pZS21 vector for ligation.  0.8% agarose gel in 0.5% 
TAE containing EtBr loaded with 10 μL digest reaction and run at 130V for 30 minutes. The sequenced 
BamA tryptophan mutant plasmids were digested overnight at 37°C with restriction enzymes EcoRI and 
XbaI, as was the parent pZS21 variant encoding GFP. The respective insert and backbone portions were 
excised and purified, resulting in a pZS21 vector and BamA inserts with complementary sticky overhangs. 
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Transformants from this 
ligation were screened by 
enzyme digest; the parent 
vector produced an insert 
less than one kilobase in 
size, while BamA is about 
2,600 base pairs long, 
allowing for unambiguous 
identification of the correct 
insert (Figure 12). 
Colonies containing the 
BamA insert were verified 
by sequencing. The 
resulting plasmids were 
two mutations of BamA, 
T53C and R160C, which 
were suitable for 
expression and therefore 
also for crosslinking 
experiments. 
Complementation Assay 
 
Single mutations to tryptophan were introduced in locations with high degrees of 
sequence conservation with the intent to target residues directly involved in the putative 
interaction between inner membrane elements and POTRAs 1 and 2 of BamA. Versions 
of BamA altered in this way are said to complement if they can “rescue” BamA-deficient 
E. coli. We acquired a useful strain of E. coli, JCM166, from the Silhavy Lab of 
Princeton University. The JCM166 strain encodes in its genome wild-type BamA under 
an arabinose promoter. In the presence of arabinose, JCM166 cells grow normally. In the 
absence of arabinose, JCM166 cells eventually die owing to their lack of functional 
BamA, which can be complemented by plasmid DNA encoding the functional protein. 
Figure 12: Colony screen by restriction digest of BamA cysteine 
mutant ligations into pET vector. 0.8% agarose gel in 0.5% TAE 
containing EtBr shows insert of interest (~3.6 Kb) is present in WT 
colonies A and B, T53C colony A, and R160C colony B. T53C colony B 
and R160C colony A returned the BamC insert present in the parent 
vector. Ligation colonies were miniprepped and digested with restriction 
enzymes NdeI and EcoRI for 1 hour at 3  C. Resulting digestion was 
loaded 10 μL per well and run at 135V for 30 minutes. 
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Inability to fully complement would suggest that the plasmid-encoded protein is 
functionally compromised. This assay thus identifies mutants for further study. With this 
in mind the three tryptophan mutants R162W, R160W, and R36W were transformed into 
JCM166 cells and grown overnight in the presence of L-arabinose, after which growth 
media was switched to media containing the control sugar D-fucose and the cells were 
passaged three times, to deplete endogenous BamA. The effect of this change on optical 
density at 600 nm was monitored over a period of five hours. Figure 14 shows the results 
of this complementation assay. 
 
 
 
 
 
 
Figure 13: Complementation assay schematic. Complementation with JCM166 E. coli cells allows for 
the determination of residues of functional importance by screening for mutations that affect cell viability 
due to impaired activity. 
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Mutants R160W and R162W complement the endogenous BamA deficiency within 
measurement error. However, the mutant R36W fails to complement somewhat 
drastically. It demonstrates more growth than the negative control strain containing GFP, 
but it is demonstrably less viable than the wild-type strain (P< 10
-5
).  
 
To test if the failure of R36W to complement BamA depletion was due to impaired 
expression, an identical number of cells expressing WT or BamA mutants were analyzed 
by Western blot using a primary antibody against BamA. This blot returned bands for 
BamA in all samples using an anti-BamA probe (Figure 15). BamA is present in all 
strains, wild type and mutant, and in similar levels by inspection of the Western blot. 
Figure 14: Complementation assay results. Optical density at 600nm was measured hourly after 
endogenous BamA was no longer expressed in complementation cells. After three passages into media 
containing the control sugar D-fucose, JCM166 E. coli cells containing plasmid encoding the control 
protein GFP failed to divide, indicating the depletion of endogenous BamA in all cells. Tryptophan 
mutants R160W and R162W appear to fully complement as their growth rate is indistinguishable within 
measurement error from the wild type positive control. However, tryptophan mutant R36W fails to 
complement unambiguously. Error bars represent standard deviation of triplicate trials. 
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Inconsistency in the running 
molecular weight of the wild-
type control is thought to be an 
experimental artifact due to 
anomalous mobility in SDS-
PAGE, as this result was not seen 
in subsequent Western blots. 
 
In order to verify that BamA is 
both properly folded and properly 
localized in the outer membrane 
forming the Beta-barrel 
Assemble Machine, histidine-
tagged plasmid-originating 
BamA was purified by Ni-NTA 
affinity column. This process 
purified BamA as well as 
whichever proteins it was 
associated with, i.e. components 
of the BAM complex. Western 
blots of antibodies against BamA 
and BamD, the two essential 
components of the BAM 
complex, showed that both 
BamA and BamD were present in 
the purified sample. This 
indicated that the construction of 
the BAM complex was 
proceeding normally, suggesting 
that the R36W mutant’s failure to 
complement was unrelated to lack 
Figure 15: Western Blot for BamA. Samples were spun 
down and resuspended according to their OD600 such that they 
would have the same number of cells per load volume. These 
samples were run on a 10% SDS-PAGE gel at 100V for ~2 
hours, transferred to a PVDF membrane, and probed with a 
primary antibody against BamA diluted 1:20,000. Blots were 
visualized via a secondary antibody conjugated to horseradish 
peroxidase, which reacts with a chemiluminescent substrate. 
BamA appears to be present in all samples.  
Figure 16: Western Blot of Ni-NTA pulldown showing the 
probable construction of the intact BAM complex. Cells 
were lysed and loaded on a Ni-NTA column and eluted with 
imidazole. Elution was used to run a Western blot as described. 
Primary antibodies against BamA and BamD were used at 
dilutions of 1:20,000 and 1:5,000, respectively. Control wells 
are purified aliquots of BamA and BamD. 
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of expression, misfolding, or mislocalization. A decrease in the mutant R36W’s amount 
of both BamA and BamD in Figure 16 is attributed to protein loss in purification. 
 
Cross-Linking Experiments 
 
Plasmids encoding 
cysteine mutants of 
BamA were 
transformed into BL-
21/DE3 E. coli cells 
and grown without 
IPTG induction to 
minimize 
transcriptional levels 
of BamA, thus 
making any 
crosslinking of cysteine mutants a larger ratio of the total and therefore easier to observe. 
Crosslinkers GMBS and SMCC (Figure 17) were chosen on the basis of membrane 
permeability, stability in reducing conditions, and the ability to react with sulfhydryls and 
amines. In this way, crosslinking can be largely directed to the specific location of the 
single cysteine residue in the cysteine-mutant BamA variants and whatever proteins they 
may be interacting with. Cells were diluted to the same optical density and processed for 
use in Western blots such that each sample had the same number of cells per load 
volume. These blots were probed with an antibody against BamA, as previously. Western 
blotting showed the presence (or absence) of high-molecular weight species detected by 
an anti-BamA antibody, indicating the presence or absence of crosslinking. Figure 18 
shows this resulting Western blot, which was again carried out with whole cell lysates. 
Figure 17: Membrane-permeable amino-to-sulfhydryl crosslinkers 
applied to in-vivo cysteine mutant crosslinking experiments. 
Crosslinkers were obtained from Thermo Scientific/Pierce Protein Biology 
Products. Images from [55, 56]. 
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 Figure 18: Western blot for BamA in crosslinked cells. Samples containing equal volumes with equal 
optical densities were run on a 10% SDS-PAGE gel at 100V for ~2 hours, transferred to a PVDF 
membrane, and probed with a primary antibody against BamA diluted 1:20,000. Blots were visualized via a 
secondary antibody conjugated to HRP reacting with a chemiluminescent substrate. 
The Western blot for BamA in crosslinked cells appears to show crosslinked BamA at 
high molecular weight, > 200 kDa with the crosslinker GMBS (boxed in Figure 18). This 
band appears only in the cysteine mutants and not the wild type control; additionally, 
bands showing BamA at its expected molecular weight (~90 kDa) is much decreased in 
the cysteine mutants, supporting the notion that BamA is crosslinking with very high 
efficiency. There is similarly a noticeable difference between the wild type and mutant 
strains when subjected to the crosslinker SMCC, but high molecular weight bands are so 
faint that efficiency is likely low. There is a high molecular weight band in the R160C 
mutant of the negative control, itself composed of the two mutants and the wild type 
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strain without crosslinker. This may be the result of BamA dimers forming between 
cysteine mutants due to inadequate reduction by dithiothreitol (DTT) present in the 
loading buffer. 
Discussion 
 
This project was highly directed by the results of the bioinformatics analysis undertaken 
with ConSurf. Encouragingly, evolutionary conservation scores calculated by the 
ConSurf server illuminated an area of highly conserved surface residues that includes 
clustered residues capable of mediating protein-protein interactions. This provided the 
rationale for the project and aided in choosing specific amino acids for mutagenesis. 
 
The fact that the conserved amino acids are localized to an area spanning POTRAs 1 and 
2, combined with the fact that this particular area of conservation is so densely populated 
with amine- and amide- containing amino acids, is highly suggestive of some mechanistic 
function. The side groups of arginine, asparagine, and glutamine are capable of 
participating in electrostatic interactions and hydrogen bonding, in addition to other 
noncovalent interactions. It has been shown that evolutionarily conserved arginines are 
common in protein-protein interfaces [57]. Arginines characteristically can form many 
types of interactions that aid in protein-protein contacts; in addition to hydrogen bonding 
(five hydrogen bonds can be accepted or donated in the case of arginine, a large number 
of interactions), arginines can form salt bridges and exhibit pi electron delocalization that 
enables them to form cation-pi interactions, largely with aromatic residues [58]. 
Additionally, arginine’s long hydrocarbon tail enables some hydrophobic interactions. 
The clustering of these residues does not point to a definitive explanation for their 
functional importance, but suggests that this area may serve as a “docking station” for 
nascent OMPs, chaperones, or the inner membrane proteins or phospholipids predicted 
by the transenvelope hypothesis. 
 
Original site-directed mutagenesis in the pET vector suitable only for cloning was 
successful, despite the potential for mispriming or lack of annealing in primers that are by 
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necessity non-complementary to the site intended to be mutated. Sequencing with T7 
promoter and terminator primers returned sequences that demonstrated the desired 
mutation and verified that no secondary, unintentional mutations were created via PCR 
cycling iterations.  
 
The preliminary mutagenesis pET vector was chosen because it was suitable for cloning 
and was sufficiently high copy number to allow for high yields of DNA purification for 
downstream applications. However, this plasmid was not the original choice for 
mutagenesis. An effort was made to mutagenize a previously created pZS21 plasmid 
encoding full-length, wild-type BamA, which could have been used directly for both 
complementation and crosslinking experiments. Site-directed mutagenesis by PCR of this 
plasmid was not successful, likely due to difficulty amplifying the parent vector, a 
process that is necessary in the Quickchange mutagenesis protocol. Thus, it was 
necessary to create mutations in the pET cloning vector described and then move these 
genes into more suitable plasmid backbones.  PCR amplification of the cysteine mutants 
and restriction digest and ligation of all inserts into both pET and pZS21 expression 
systems was successful, as shown by restriction digest check (in the case of the cysteine 
mutants in pET plasmids) and subsequently sequencing with appropriate primers (in the 
case of both the pET cysteine mutants and the pZS21 tryptophan mutants). 
 
In the complementation assay, it was particularly important to ensure that any loss of 
function was due exclusively to impairment of an interaction in which the residue of 
interest participated, rather than lack of expression, solubility, or mislocalization. Recall 
that the use of tryptophan scanning to investigate functional importance of the residues 
identified for study was justified on the basis that mutations to a large, sterically 
hindering amino acid would effectively block interactions between the BamA POTRA 
domains and other proteins. In contrast to alanine or leucine scanning, single mutations to 
tryptophan are more informative and potentially catastrophic to function in interactions 
between proteins; however, such a dramatic change could potentially affect the proper 
folding and insertion of BamA.  
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Western blotting for BamA in all mutants showed appreciable levels of the protein, 
indicating that expression was unaffected (Figure 15). A limitation of this particular test 
is that the antibody used for the blot was non-specific for histidine-tagged BamA; in 
order to unequivocally show that JCM166 E. coli cells are rescued (or not) by plasmid-
originating DNA, it would be necessary to blot using a more specific antibody, like an 
anti-histidine tag probe.  
 
Western blots of Ni-NTA purified BamA effectively circumvented this limitation, as the 
purification process is also specific for histidine-tagged, plasmid-originating BamA, and 
they showed that BamA assembles with BamD in the BAM complex regardless of the 
R36W mutation. This shows that the R36W mutation does not cause aggregation or 
difficulties inserting into the outer membrane. A more complete test of the construction 
of the BAM complex would require blotting with antibodies against all five proteins; 
BamA and BamD were chosen in this case because they are the only essential 
components of the complex. Alternatively, purification of the outer membrane and 
subsequent Western blotting would robustly show that the R36W mutant is in fact 
inserted into the outer membrane and associates with BamB-E. However, the Western 
blot of Ni-NTA purified BamA showed that BamA was interacting with BamD, which 
would be highly improbable unless both proteins were properly folded and localized. 
This makes the finding that the R36W mutant fails to complement very significant, and 
implies that this particular residue is mechanistically important for the function of BamA. 
 
This fact, that a mutation between POTRAs 1 and 2 impairs the function of the entire 
periplasmic domain, is an interesting finding because deletions of the entire POTRA1 and 
2 domains have been shown to be non-lethal in E. coli, although the sigma
E 
SOS response 
is upregulated. [34]. Membrane permeability is altered, and these mutant phenotypes tend 
to display changes in outer membrane composition and an increase in the number of mis-
folded OPMS, but POTRA1 and 2 deletions do not halt replication of E. coli. Thus, the 
fact that the R36W mutation in the bridge between POTRAs 1 and 2 fails to complement 
could lead to new understanding of the mechanism of OMP insertion. A possible 
explanation is that, while a truncated version of the periplasmic domain of BamA can be 
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compensated for by the protein chaperones or other mechanisms, introducing a 
tryptophan mutation in this location causes the POTRA arm to “stall,” blocking its 
mechanism in a way that is catastrophic to OMP insertion. 
 
The identification of a residue that appears critical for BamA function is not necessarily 
supportive of the hypothesis that the POTRA domains forms a trans-periplasmic folding 
envelope while interacting with inner membrane components. An alternative possibility 
is that R36 is involved in the conformational change of the POTRA arm (see Figure 5). It 
would be beneficial to repeat SAXS experiments comparing the wild-type and R36W 
mutant to see if conformations are altered or impaired, although the placement of R36 
makes this possibility unlikely. Another possibility is that SurA, which has been shown to 
interact with BamA via crosslinking studies, is somehow blocked from docking by this 
tryptophan mutation [44]. These crosslinking studies could be repeated with the R36W 
mutant with an additional cysteine, to attempt to see if crosslinks can still be created. 
Again, this possibility is unlikely given that deletions of SurA do not give a lethal 
phenotype. The same is true for other BAM proteins (other than BamD, which can be 
ruled out by Figure 16) that may be blocked from scaffolding to BamA 
 
Alternatively, R36W could be impeding the formation of the hypothetical 
transperiplasmic folding envelope. This in part supports why crosslinking experiments 
were successful. These crosslinking experiments could be repeated with R36W-cysteine 
mutants to see if the substitution of tryptophan at position 36 impairs the formation of 
such an envelope. 
 
Crosslinking experiments with T53C and R160C also suggested areas for further 
experimentation. Figure 18 is highly suggestive of crosslinks forming between both 
cysteine mutants with the crosslinker GMBS, which is more flexible than the alternative 
SMCC. T53 is on the tip of POTRA1 and was chosen due to its hypothetical proximity to 
the inner membrane when the POTRA domains assume their extended conformation. T53 
is also a residue that has a conservation score of 4, meaning it is somewhat conserved 
among homologs. By contrast, R160C is located in the highly conserved patch of 
   
29 
 
arginines between POTRAs 1 and 2, and it has a top conservation score of 9. Despite this 
difference, both mutants show high molecular weight bands, although T53 has a band 
slightly higher than R160C (Figure 18). 
 
One possible explanation for this high molecular weight species is the formation of 
disulfide bonds between cysteine-mutant BamA, resulting in oligomers. Although the 
reducing agent DTT was present in the loading dye used to run the SDS-PAGE gel for 
Western blotting and samples were boiled prior to loading (an action necessary for the 
denaturation of membrane beta barrels), it is possible that disulfide bonds were not fully 
reduced. Alternatively, non-reducible crosslinks may be occurring between multiple 
BamA subunits. This would be an interesting outcome, as it has been suggested in in 
vitro studies that elements of the BAM complex oligomerize [59]. 
 
However, there are multiple possible explanations for the crosslinked species seen in 
Figure 18. It is known that POTRA 5 scaffolds the BamCDE subcomplex mediated by 
the essential lipoprotein BamD; POTRAs 3 and 4 also appear to have a role in 
scaffolding [34, 35]. The molecular weight marker identifies the presumed crosslinked 
bands to be more than 200 kDa in size. The complete BAM complex in a 1:1:1:1:1 ratio 
is not this large, and neither is any one component of the BAM complex linked with 
BamA a sufficient explanation for bands at molecular weights in excess of 200 kDa—
BamA, B, C, D, and E have molecular weights of ~90, 40, 30, 25, and 12 kDa, 
respectively—and heat denaturation would break apart any non-crosslinked interactions 
between BAM complex components  
 
It is tempting to propose that the Sec translocon interacts directly with POTRA 1-2 of 
BamA. This would be the simplest form of a transenvelope assembly, as SecYEG 
translocates OMPs to the periplasm and has been suggested to partner with the BAM 
complex in two-partner secretion [21, 60]. However, The SecYEG monomer weighs 75 
kDa. This, too, does not satisfactorily explain the high molecular weight bands seen in 
Figure 18. It is possible that the crosslinked species observed have anomalous mobility in 
the SDS-PAGE gel due to crosslinks causing uneven coating by SDS or other factors 
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affecting charge-to-mass ratio or steric barriers to migration through acrylamide pores. 
This makes it difficult to rule out the possibility of crosslinking with any known protein. 
Thus, crosslinked bands will be excised and digested by trypsin for analysis by mass 
spectrometry, enabling the comparison of the crosslinked entity to a library of possible 
proteins. In this way, the crosslinked species may be identified. 
 
In conclusion, the experiments described here provide tantalizing evidence that the 
phylogenetically conserved patch of residues in POTRAs 1 and 2 that include R36 
play a crucial role in BamA function. This is in stark contrast to the prevailing view 
in the field that POTRA1 and 2 are “disposable.” Furthermore, the efficient 
crosslinking observed with single cysteine BamA mutants, particularly when using 
GMBS, suggests that BAM does indeed form higher order assemblies. Whether the 
assembly is with inner membrane components or due to oligomerization of BAM 
awaits the mass spectrometry identification of the crosslinked products.  
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Materials and Methods 
 
ConSurf Bioinformatics analysis: The following parameters were run using the ConSurf Server: 
 
 
 
 
Site-directed mutagenesis: Parent plasmid pMS629, a pET41a(+) variant encoding full-length BamA 
created by Troy Walton, was used in the Quickchange method for site-directed mutagenesis (Stratagene 
protocol). Synthetic mutagenic oligonucleotide primers were designed and ordered from Integrated DNA 
Technologies (IDT), Inc. (See Table 1).  
Mutation Primer sequence, 5’-3’ 
R36W 5’- CGCACCAACGGCGACccaCTGAAGGCCTTCGAAATG -3’ 
5’- CATTTCGAAGGCCTTCAGtggGTCGCCGTTGGTGCG-3’ 
R160W 5’-CACCAGTTTTAGGTCAACccaGTTGCGCGGCAGCGGGGTC-3’ 
5’-GACCCCGCTGCCGCGCAACtggGTTGACCTAAAACTGGTG-3’ 
R162W 5’-CAGTTTTAGGTCAACACGGTTccaCGGCAGCGGGGTCACGACAGC-3’ 
5’- GCTGTCGTGACCCCGCTGCCGtggAACCGTGTTGACCTAAAACTG -3’ 
T53C 5’- GATATCTTCATCATTAACacaGTCGCCTGTGCGCACCGG-3’ 
5’- CCGGTGCGCACAGGCGACtgtGTTAATGATGAAGATATC-3’ 
R160C 5’-CACCAGTTTTAGGTCAACacaGTTGCGCGGCAGCGGGGTC-3’ 
5’-GACCCCGCTGCCGCGCAACtgtGTTGACCTAAAACTGGTG-3’ 
 
 
These oligonucleotide primers were used in the following 50 μL PCR reactions: 37 μL diH2O + 5 μL 10x 
pfu Turbo Cx polymerase buffer (New England Biolabs, NEB) + 2.5 μL each upper and lower primers (5 
μM) + 1.5 μL dNTP mix (10 mM, NEB) + 1 μL pMS629 parent (100 ng/μL) + 0.5 μL pfu Turbo Cx 
polymerase (NEB). Thermocycling parameters were as follows: 1) 95°C for 5 minutes 2) 95°C for 1 minute 
3) 55°C for 1 minute 4) 68°C annealing temperature for 3 minutes; repeat 2-5 eighteen times  5) 55°C 1 
minute, 6) 68°C 30 minutes, and 7) hold at 4°C until further experimentation. 1 μL per 50μL PCR reaction 
of restriction enzyme DpnI (NEB) was added to PCR products and incubated at 37°C overnight to digest 
methylated parent vector DNA, leaving mutant plasmid copies for use in further experiments. To verify 
appreciable amplification of mutant plasmid, 10μL of post-DpnI digested PCR product was run on 0.8% 
agarose gel in 0.5x tris-acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA ) at 135 
V for 30 minutes and stained with ethidium bromide (EtBr) (an intercalator) and visualized at wavelength 
302nm.  
 
Remaining DpnI-digested PCR products were used to transform XL-10 gold E. coli competent cells 
(Agilent Technologies): 10μL of PCR product were introduced to 100μL aliquots of chemically competent 
XL-10 gold cells and placed on ice for 30 minutes. Cells were heat-shocked at 42°C for 45 seconds, placed 
on ice for 1 minute, and were suspended to a final volume of 1 mL in luria broth (Sigma-Aldrich) before 
incubation at 37°C, with agitation, for 45 minutes. Cell suspension was spun at 3000 rpm for 10 minutes, 
Table 1: Primer sequences for site-directed mutagenesis of BamA 
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after which supernatant was discarded, cells were resuspended in 200uL LB, and plated on agar plates 
containing 50 μg/ml kanamycin, a selecting antibiotic. Colonies resulting from this transformation were 
used to inoculate 5mL aliquots of LB containing 50 μg/mL kanamycin for use in Quiagen miniprep kits. 
Purified DNA from said miniprep kit (average concentration 100ng/μL) was sent for sequencing (ACGT, 
Inc.) to verify mutation and frozen at -20°C for downstream applications.  
 
Digestion of tryptophan mutants for ligation into pZS21 vector: pMS598, a pZS21 variant encoding GFP 
and a kanamycin resistance cassette, was doubly digested with EcoRI and XbaI (NEB) for 12 hours at 37°C 
in the Cutsmart buffer system (NEB). Sample reaction:   μL pMS598 (100ng/μL) + 1 μL EcoRI + 1 μL 
XbaI + 1 μL Cutsmart buffer. Vector was gel-purified using Quiagen gel extraction kit. BamA pET mutants 
were digested and purified in the same fashion. Ligations were done in a 1:3 vector: insert ratio for 16 
hours at 4°C. Sample reaction: 3 μL insert + 3 μLvector + 1 μL T4 Ligase buffer (NEB) + 1 μL T4 Ligase 
(NEB) + 2 μL diH2O. Resulting colonies of XL-10 gold cells plated on Kanamycin-containing agar were 
then miniprepped as described and sequenced using Upper and Lower 566 BamA sequencing primers via 
ACGT, Inc. 
 
Digestion of cysteine mutants for ligation into pET41a(+) vector for expression: pMS282, a pET plasmid 
encoding BamC and a kanamycin resistance cassette created by Jen Liddle was doubly digested as 
described, though using the restriction enzymes NdeI and EcoRI, which are compatible in the NEB 3 buffer 
system. PCR amplification primers were designed to amplify BamA cysteine mutants directly from pET 
cloning vector: 
5’-TGC TTA GAA TTC TTA CCA GGT TTTACC GAT G-3’ Adds EcoRI site to 3’ end of coding 
strand 
5’-TAA GCA CAT ATG GCG ATG AAA AAG TTG CTC-3’ 
 
Adds NdeI site to 5’ end of coding strand 
Table 2: Primers intended to amplify BamA and add NdeI and EcoRI sites. 
 
PCR program was run as described. Amplified inserts were digested with DpnI, again as described, and 
digested with NdeI and EcoRI after PCR purification (Quiagen kit) to remove DpnI. Ligations were done in 
as previously and transformed into XL-10 gold cells on kanamycin selective plates. Resulting colonies 
were miniprepped and screened via enzyme digest (as described) with NdeI and EcoRI; visualization via 
UV imager at 302nm of 0.8% agarose gel in 0.5% TAE containing EtBr and 10 μL each miniprepped 
plasmid showed which colonies contained insert of interest after running at 130V for 30 minutes. Plasmids 
with correct insert were sent to ACGT, Inc. for sequencing with T7 promoter and terminator primers. 
 
Complementation assay: Tryptophan mutants mutations R162W, R160W, and R36W were transformed 
into JCM166 E. coli cells (Silhavy Group, Princeton University) according to the protocol outlined above, 
and streaked onto LB-agarose plates containing 50 μg/mL Kanamycin and 20% (w/v) agarose. Single 
colonies were selected from these plates and grown overnight at 37°C with agitation in 5 mL LB + 0.05% 
(w/v) L-arabinose. These cultures were diluted to OD600 = 0.025 in new, warmed media (5 mL) containing 
the control sugar D-fucose. Cultures were incubated at 37°C with aeration provided by a rotating shaker 
and allowed to grow to OD600 = 0.6, with OD600 measurements hourly. At OD600 = 0.6, trials were 
subcultured again to OD600 = 0.025, and monitored as described. This pattern was repeated until GFP 
control exhibited no growth and stable optical density, which in practice translated to three passages from 
overnight culture. Experiments were performed in triplicate.  
 
Western blotting of complementation samples: Culture samples were taken following the culmination of the 
assay for use in western blotting: 100mL of each strain was grown and passaged as above. After five hours 
after the final passage, OD600 was measured and cells were diluted such that the final load for western blots 
would result in comparable levels of protein across all trials. Cells were resuspended in 200μL 1x SDS-
PAGE loading dye containing 50mM dithiothreitol (DTT, Thermo), boiled 10 minutes, and spun at 
14,000xg for 10 minutes before loading on 10% SDS-PAGE gel and run at 100 V for ~2 hours. Protein 
from gel was transferred using Pierce Fast Semi-Dry Transfer protocol on polyvinylidine fluoride (PVDF, 
Pierce) membranes with transfer taking place at 20V for 20 minutes. Membranes were blocked 16 hours at 
4°C in 5% milk in TBS (10 mM TrisCl, pH 7.5, 150 mM NaCl), washed with TBS containing 0.5% v/v 
Tween-20 and 0.2% Triton X-100 (Sigma), and probed with UCO180 anti-BamA antibody diluted 
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1:20,000 in 5% milk in TBS for 1 hour at ambient temperature (antibody obtained from Petia Gatzeva-
Topalova). TBS-Tween-Triton washes continued, and finally blots were exposed to Horseradish 
Peroxidase-conjugated AffiniPure Donkey anti-Rabbit IgG (Jackson Research) at dilution 1:10,000 in 7% 
milk in TBS. Immobilon Western Chemiluminescent HRP Substrate (Millipore) was used to visualize 
bands according to manual. 
 
Crosslinking experiments: Cysteine mutants T53C and R160C were transformed into BL-21/DE3 cells 
following the same protocol described. Single colonies resulting from this transformation were grown 
overnight at 37°C with agitation in LB medium containing 50 μg/mL kanamycin. This culture was used to 
inoculate 25 mL LB containing kanamycin. Cells were grown to OD600 = 0.6 at 37°C with shaking and 
diluted to equal OD600 to minimize loading errors. Cells were then spun at 3,000 rpm, and washed twice 
with GMBS/SMCC crosslinking buffer (20 mM Sodium phosphate pH 7.5, 150 mM NaCl, 1 mM EDTA) 
and treated with crosslinkers GMBS or SMCC (Thermo) to a final concentration of 0.2 mM after 
resuspension in 5 mL crosslinking buffer. Cultures were incubated with crosslinker 30 minutes at room 
temperature with mild agitation. After incubation, crosslinking reaction was quenched with 20mM L-
cysteine for 5 minutes shaking at room temperature. Cells were pelleted by centrifugation at 3,000 rpm and 
resuspended in 200 μL SDS-PAGE loading buffer containing 50mM DTT. Cells were vortexed, boiled 10 
minutes at 95°C, cooled on ice, vortexed again, and spun 10 minutes at 14,000 rpm to achieve cell lysis. 
Samples were stored at -20°C until Western blot experiments were begun, according to the same protocol 
outlined above. 
 
Ni-NTA Pulldown of BamA from Complementation Cells: Complementation cells were processed such that 
resuspension would result in the same number of cells/volume. Cells were resuspended in BugBuster lysis 
buffer (Millipore) and allowed to incubate for 1 hour at room temperature. The supernatant from this 
mixture when spun at 3000 rpm for 30 minutes was loaded on an equilibrated Ni-NTA (Quiagen) column at 
pH 7.5. Histidine-tagged BamA was eluted with 200mM imidazole after washes with low imidazole buffer. 
Elution was added to SDS-PAGE 2x loading buffer containing 50mM DTT and boiled for 10 minutes at 
95°C before use in Western blot. Blotting for BamA took place as described. Blotting for BamD used a 
first-bleed antibody, UCO177, against BamD in dilutions of 1:5,000 in 5% milk for 1 hour at room 
temperature (antibody from Petia Gatzeva-Topalova). Secondary antibody and chemiluminescent reagent 
for visualization were added as described.  
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